Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-03-06
2007-03-06
Nguyen, Quang (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S455000, C435S320100
Reexamination Certificate
active
10855559
ABSTRACT:
The present invention provides therapeutic compositions and methods for vector-mediated delivery and in vivo expression of polynucleotides encoding anti-cancer compounds that are effective in the treatment of cancer. In particular, the invention relates to the use of recombinant viral and non-viral vectors to deliver genes encoding one or more anti-angiogenic or proapoptotic gene products for the treatment of cancer.
REFERENCES:
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5686279 (1997-11-01), Finer et al.
patent: 5712380 (1998-01-01), Kendall et al.
patent: 5736129 (1998-04-01), Medenica et al.
patent: 5753500 (1998-05-01), Shenk et al.
patent: 5872005 (1999-02-01), Wang et al.
patent: 5955311 (1999-09-01), Rockwell et al.
patent: 5994106 (1999-11-01), Kovesdi et al.
patent: 6011003 (2000-01-01), Charnock-Jones et al.
patent: 6040183 (2000-03-01), Ferrari et al.
patent: 6093570 (2000-07-01), Ferrari et al.
patent: 6127175 (2000-10-01), Vigne et al.
patent: 6133028 (2000-10-01), Imler et al.
patent: 6156303 (2000-12-01), Russell et al.
patent: 6180613 (2001-01-01), Kaplitt et al.
patent: 6287814 (2001-09-01), Hope et al.
patent: 6503888 (2003-01-01), Kaplitt et al.
patent: 6548286 (2003-04-01), Samulski et al.
patent: 6780409 (2004-08-01), During et al.
patent: 2002/0168342 (2002-11-01), Wang et al.
patent: 2003/0017977 (2003-01-01), Xia et al.
patent: 2003/0228282 (2003-12-01), Gao et al.
patent: 2004/0005684 (2004-01-01), Hung et al.
patent: 2004/0057933 (2004-03-01), Wilson et al.
patent: WO 97/44453 (1997-11-01), None
patent: WO 98/13071 (1998-04-01), None
patent: WO 99/61066 (1999-12-01), None
patent: WO 00/75319 (2000-12-01), None
patent: WO 02/060489 (2002-08-01), None
Verma et al. Gene Therapy: Twenty-first century medicine. Annu. Rev. Biochem. 74:711-738, 2005.
Goncalves, M. A concise peer into the background, initial thoughts and practices of human gene therapy. BioEssays 27:506-517, 2005.
Gardlik et al. Vectors and delivery systems in gene therapy. Med. Sci. Monit. 11(4):RA110-121, 2005.
Altschul et al., “Basic Local Alignment Search Tool”, J. Mol. Biol., 215:403-410 (1990).
Ashkenazi, “Targeting Death and Decoy Receptors of the Tumour-Necrosis Factor Superfamily”, Nat. Rev. Cancer, 2:420-430 (2002).
Bergers et al., “Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice”, Science, 284:808-811 (1999).
Batzer et al., “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3'-terminus”, Nucleic Acids Res., 19:5081 (1991).
Bobo et al., “Convection-enhanced delivery of macromolecules in the brain”, PNAS, 91(6):2076-2080 (1994).
Bossis and Chiorini, “Cloning of an Avian Adeno-Associated Virus (AAAV) and Generation of Recombinant AAAV Particles”, J. Virol, 77(12):6799-6810 (2003).
Byrne et al., “Vascular Endothelial Growth Factor-Trap Decreases Tumor Burden, Inhibits Ascites, and Causes Dramatic Vascular Remodeling in an Ovarian Cancer Model”, Clin. Can. Res., 9:5721-5728 (2003).
Capecchi, “High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells”, Cell, 22:479-488 (1980).
Chiorini et al., “Cloning and Characterization of Adeno-Associated Virus Type 5”, J. Virol., 73(2):1309-1319 (1999).
Cunningham et al., “Distribution of AAV-TK Following Intracranial Convection-Enhanced Delivery Into Rats”, Cell Transplantation, vol. 9:585-594 (2000).
Davidson et al., “Recombinant adeno-associated virus type 2, 4, and 5 vectors” Transduction of variant cell types and regions in the mammalian central nervous system, PNAS, 97(7):3428-3432 (2000).
Donnelly et al., “The cleavage activities of aphthovirus and cardiovirus 2A proteins”, J. Gen. Virol., 78:13-21 (1997).
Dull et al., “A Third-Generation Lentivirus Vector with a Conditional Packaging System”, J. Virology, 72(11):8463-8471 (1998).
Felgner et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure”, Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987).
Furler et al., “Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons”, Gene Therapy, 8(11):864-873 (2001).
Gao et al., “Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy”, PNAS, 99(18):11854-11859 (2002).
Gao et al., “Adeno-associated viruses undergo substantial evolution in primates during natural infections”, PNAS, 100(10):6081-6086 (2003).
Gengrinovitch et al., “Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF121and VEGF165Using Several Concurrent Mechanisms”, J. Biol. Chem., 270:15059-15065 (1995).
Griscelli et al., “Angiostatin gene transfer: Inhibition of tumor growthin vivoby blockage of endothelial cell proliferation associated with a mitosis arrest”, Proc. Natl. Acad. Sci. USA, 95(11):6367-6372 (1998).
Guo et al., “Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer”, Gene Ther., 3(9):802-810 (1996).
Hagedorn et al., “Domain Swapping in a COOH-terminal Fragment of Platelet Factor 4 Generates Potent Angiogenesis Inhibitors” Cancer Research, 62(23):6884-6890 (2002).
Halbert et al., “Repeat Transduction in the Mouse Lung by Using Adeno-Associated Virus Vectors with Different Serotypes”, Journal of Virology, 74(3):1524-1532 (2000).
Hanahan et al., “Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes”, Nature, 315(6015):115-122 (1985).
Harbury et al., “A Switch Between Two-, Three-, and Four-Stranded Coiled Coils in GCN4 Leucine Zipper Mutants”, Science, 262:1401-1407 (1993).
Hartley et al., “Naturally Occurring Murine Leukemia Viruses in Wild Mice: Characterization of a New “Amphotropic” Class”, J. Virol., 19:19-25 (1976).
Hiraga et al., “The Bisphosphonate Ibandronate Promotes Apoptosis in MDA-MB-231 Human Breast Cancer Cells in Bone Metastases”, Cancer Res., 61(11):4418-4424 (2001).
Holash et al., “VEGF-Trap: A VEGF blocker with potent antitumor effects”, PNAS, 99(17):11393-11398 (2002).
Horoszewicz et al., “LNCaP Model of Human Prostatic Carcinoma”, Cancer Res., 43(4):1809-1818 (1983).
Huang, et al., “Regression of established tumours and metastases by potent vascular endothelial growth factor blockade”, Proc. Nat. Acad. Sci. USA, 100(13):7785-7790 (2003).
Kim et al, “Use of the human clongation factor 1α promoter as a versatile and efficient expression system”, Gene, 91(2):217-223 (1990).
Kim et al., “Potent VEGF blockage causes regression of coopted vessels in a model of neuroblastoma”, Proc. Nat. Acad. Sci. USA, 99(17):11399-11404 (2002).
Lin et al., “Inhibition of Tumor Growth by Targeting Tumor Endothelium Using a Soluble Vascular Endothelial Growth Factor Receptor”, Cell Growth Differ., 9(1):49-58 (1998).
Liu et al., “Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA”, Gene Ther., 6:1258-1266 (1999).
Lucas et al., “Multiple Forms of Angiostatin Induce Apoptosis in Endothelial Cells”, Blood, 92(12):4730-4741 (1998).
Maione et al., “Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides”, Science, 237:77-79 (1990).
Mannino et al., “Liposome Mediated Gene Transfer”, Bio Techn., 6:682-690 (1988).
McCarty et al., “Self-complementary recombinant adeno-associated virus (scAAV) vectors promoter efficient transduction independently of DNA synthesis”, Gene Ther., 8(16):1248-1254 (2001).
Miller, “Human gene therapy comes of age”, Nature, 357:455-460 (1992).
Mulligan et al.,
Donahue Brian
Harding Thomas
Jooss Karin
Lalani Alshad
Cell Genesys Inc.
DLA Piper (US) LLP
Nguyen Quang
LandOfFree
Method for treating cancer by vector-mediated delivery of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating cancer by vector-mediated delivery of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating cancer by vector-mediated delivery of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3765028